Senti Biosciences Holdings, Inc. (SNTI) Fair Value 2026

SNTI · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.6 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (53/100)

Quick Summary — As of 2026-08-28, Senti Biosciences Holdings, Inc. (SNTI) trades at $0.38. QOC: 4.6/10. Value Trap Risk: 53/100 (WARN). 1/13 models active.

Key Facts

Ticker
SNTI
Price
$0.38
Quality Score
4.6/10
Value Trap Risk
53/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +73.5% upside with 28% confidence
Risk: Value Trap score of 53 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give SNTI?

1 Intrinsic Value Models vs. Current Price ($0.38)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.65 +73.5%

All Models Active

All 1 models are displayed above.

What Is Senti Biosciences Holdings, Inc. (SNTI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Senti Biosciences Holdings, Inc.. Trading at $0.38 against an estimated intrinsic value of $0.65, 1 of 1 active models flag meaningful upside of +73.5% at the median.

What Do the Models Say About SNTI?

1 of 13 models are currently active for SNTI. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does SNTI Rank in Biotechnology?

Among 625 Biotechnology stocks, SNTI ranks #419 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Senti Biosciences Holdings, Inc.'s positioning within the Biotechnology segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including breakthrough therapy designations — shape both the opportunity set and risk profile.

Is SNTI a Value Trap?

CirclFi's Value Trap algorithm assigns SNTI a score of 53/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Senti Biosciences Holdings, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Senti Biosciences Holdings, Inc. earns a quality score of 4.6/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SNTI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SNTI's 1 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Senti Biosciences Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

AXIMAXIM Biotechnologies, Inc.QOC 4.6NTHINeOnc Technologies Holdings, Inc.QOC 4.6NMRANeumora Therapeutics, Inc.QOC 4.6AVTXAvalo Therapeutics, Inc.QOC 4.6BMEABiomea Fusion, Inc.QOC 4.6MNPRMonopar Therapeutics Inc.QOC 4.6PCSAProcessa Pharmaceuticals, Inc.QOC 3.5IONSIonis Pharmaceuticals, Inc.QOC 6.4AVIRAtea Pharmaceuticals, Inc.QOC 5.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: AXIM · NTHI · NMRA · AVTX · BMEA · MNPR · PCSA · IONS · AVIR · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SNTI?

4 companies across all industries closest to SNTI’s Quality of Company score of 4.6/10.

RITEMineralRite CorporationQOC 4.6JTAIJet.AI Inc.QOC 4.6DXRDaxor CorporationQOC 4.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RITE · JTAI · DXR · NVDA

Where Does SNTI Sit in CirclFi's Biotechnology Rankings?

SNTI is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Senti Biosciences Holdings, Inc.’s Valuation?

What is Senti Biosciences Holdings, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Senti Biosciences Holdings, Inc. (SNTI). The Quality of Company score is 4.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SNTI overvalued or undervalued right now?

At $0.38, 1 of 1 active models suggest SNTI may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Senti Biosciences Holdings, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.6 mean for SNTI?

Senti Biosciences Holdings, Inc.'s QOC of 4.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on SNTI?

CirclFi analyzes SNTI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is SNTI a value trap in 2026?

Senti Biosciences Holdings, Inc.'s Value Trap score is 53/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Senti Biosciences Holdings, Inc. (SNTI) a Quality of Company score of 4.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SNTI/ · Methodology
Primary sources for this SNTI valuation
  • Financial statements: Senti Biosciences Holdings, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001854270) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SNTI as of ; valuations recomputed .